Resveratrol activates autophagic cell death in prostate cancer cells via downregulation of STIM1 and the mTOR pathway

Molecular Carcinogenesis

Volumn 55, Issue 5, 2016, Pages 818-831

  Selvaraj, Senthil ^a,b   Sun, Yuyang ^a   Sukumaran, Pramod ^a   Singh, Brij B ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b QATAR CARDIOVASCULAR RESEARCH CENTER   (Qatar)

Author keywords

Autophagy; ER stress; Orai1; Prostate cancer; Resveratrol; SOCE; STIM1; TRPC1

Indexed keywords

1 [2 (4 METHOXYPHENYL) 2 [3 (4 METHOXYPHENYL)PROPOXY]ETHYL] 1H IMIDAZOLE; CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL 1; MAMMALIAN TARGET OF RAPAMYCIN; RESVERATROL; STROMAL INTERACTION MOLECULE 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; 1-(2-(3-(4-METHOXYPHENYL)PROPOXY)-4-METHOXYPHENYLETHYL)-1H-IMIDAZOLE; ANTINEOPLASTIC AGENT; CALCIUM; IMIDAZOLE DERIVATIVE; MEMBRANE PROTEIN; MTOR PROTEIN, HUMAN; STILBENE DERIVATIVE; STIM1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DU145 CELL LINE; ENDOPLASMIC RETICULUM STRESS; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PC3 CELL LINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; MALE; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; AUTOPHAGY; CALCIUM; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; MALE; MEMBRANE PROTEINS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; STILBENES; STROMAL INTERACTION MOLECULE 1; TOR SERINE-THREONINE KINASES;

EID: 84942533985     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22324     Document Type: Article

References (65)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
2. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014; 64:252-271.
3. Denis LJ, Griffiths K. Endocrine treatment in prostate cancer. Semin Surg Oncol 2000; 18:52-74.
4. Prevarskaya N, Skryma R, Shuba Y. Ca2+ homeostasis in apoptotic resistance of prostate cancer cells. Biochem Biophys Res Commun 2004; 322:1326-1335.
5. Vanoverberghe K, Vanden Abeele F, Mariot P, et al. Ca2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. Cell Death Differ 2004; 11:321-330.
6. Shapovalov G, Skryma R, Prevarskaya N. Calcium channels and prostate cancer. Recent Pat Anticancer Drug Discov 2013; 8:18-26.
7. Flourakis M, Prevarskaya N. Insights into Ca2+ homeostasis of advanced prostate cancer cells. Biochim Biophys Acta 2009; 1793:1105-1109.
8. Morelli MB, Amantini C, Nabissi M, et al. Cross-talk between alpha1D-adrenoceptors and transient receptor potential vanilloid type 1 triggers prostate cancer cell proliferation. BMC Cancer 2014; 14:921.
9. Thebault S, Flourakis M, Vanoverberghe K, et al. Differential role of transient receptor potential channels in Ca2+ entry and proliferation of prostate cancer epithelial cells. Cancer Res 2006; 66:2038-2047.
10. Zhang L, Barritt GJ. Evidence that TRPM8 is an androgen-dependent Ca2+ channel required for the survival of prostate cancer cells. Cancer Res 2004; 64:8365-8373.
11. Fixemer T, Wissenbach U, Flockerzi V, Bonkhoff H. Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer: A novel prognostic marker for tumor progression. Oncogene 2003; 22:7858-7861.
12. Weaver EM, Zamora FJ, Puplampu-Dove YA, Kiessu E, Hearne JL, Martin-Caraballo M. Regulation of T-type calcium channel expression by sodium butyrate in prostate cancer cells. Eur J Pharmacol 2015; 749:20-31.
13. Skryma R, Mariot P, Bourhis XL, et al. Store depletion and store-operated Ca2+ current in human prostate cancer LNCaP cells: Involvement in apoptosis. J Physiol 2000; 527:71-83.
14. Li N, Zheng L, Lin P, Danielpour D, Pan Z, Ma J. Overexpression of Bax induces down-regulation of store-operated calcium entry in prostate cancer cells. J Cell Physiol 2008; 216:172-179.
15. Flourakis M, Lehen'kyi V, Beck B, et al. Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells. Cell Death Dis 2010; 1:e75.
16. Vanden Abeele F, Lemonnier L, Thebault S, et al. Two types of store-operated Ca2+ channels with different activation modes and molecular origin in LNCaP human prostate cancer epithelial cells. J Biol Chem 2004; 279:30326-30337.
17. Vanden Abeele F, Shuba Y, Roudbaraki M, et al. Store-operated Ca2+ channels in prostate cancer epithelial cells: Function, regulation, and role in carcinogenesis. Cell Calcium 2003; 33:357-373.
18. Liao Y, Erxleben C, Abramowitz J, et al. Functional interactions among Orai1, TRPCs, and STIM1 suggest a STIM-regulated heteromeric Orai/TRPC model for SOCE/Icrac channels. Proc Natl Acad Sci USA 2008; 105:2895-2900.
19. Lewis RS. The molecular choreography of a store-operated calcium channel. Nature 2007; 446:284-287.
20. Prevarskaya N, Skryma R, Shuba Y. Calcium in tumour metastasis: New roles for known actors. Nat Rev Cancer 2011; 11:609-618.
21. Aluyen JK, Ton QN, Tran T, Yang AE, Gottlieb HB, Bellanger RA. Resveratrol: Potential as anticancer agent. J Diet Suppl 2012; 9:45-56.
22. Delmas D, Lancon A, Colin D, Jannin B, Latruffe N. Resveratrol as a chemopreventive agent: A promising molecule for fighting cancer. Curr Drug Targets 2006; 7:423-442.
23. Hudson TS, Hartle DK, Hursting SD, et al. Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms. Cancer Res 2007; 67:8396-8405.
24. Kim YA, Rhee SH, Park KY, Choi YH. Antiproliferative effect of resveratrol in human prostate carcinoma cells. J Med Food 2003; 6:273-280.
25. Jasinski M, Jasinska L, Ogrodowczyk M. Resveratrol in prostate diseases-a short review. Cent European J Urol 2013; 66:144-149.
26. Pani B, Ong HL, Brazer SC, et al. Activation of TRPC1 by STIM1 in ER-PM microdomains involves release of the channel from its scaffold caveolin-1. Proc Natl Acad Sci USA 2009; 106:20087-20092.
27. Singh BB, Lockwich TP, Bandyopadhyay BC, et al. VAMP2-dependent exocytosis regulates plasma membrane insertion of TRPC3 channels and contributes to agonist-stimulated Ca2+ influx. Mol Cell 2004; 15:635-646.
28. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000; 1:11-21.
29. Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: Dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 2003; 4:517-529.
30. Yuan JP, Zeng W, Huang GN, Worley PF, Muallem S. STIM1 heteromultimerizes TRPC channels to determine their function as store-operated channels. Nat Cell Biol 2007; 9:636-645.
31. Pani B, Ong HL, Liu X, Rauser K, Ambudkar IS, Singh BB. Lipid rafts determine clustering of STIM1 in endoplasmic reticulum-plasma membrane junctions and regulation of store-operated Ca2+ entry (SOCE). J Biol Chem 2008; 283:17333-17340.
32. Liu X, Cheng KT, Bandyopadhyay BC, et al. Attenuation of store-operated Ca2+ current impairs salivary gland fluid secretion in TRPC1(-/-) mice. Proc Natl Acad Sci USA 2007; 104:17542-17547.
33. Kaufman RJ. Stress signaling from the lumen of the endoplasmic reticulum: Coordination of gene transcriptional and translational controls. Genes Dev 1999; 13:1211-1233.
34. Derouiche S, Warnier M, Mariot P, et al. Bisphenol A stimulates human prostate cancer cell migration remodelling of calcium signalling. Springerplus 2013; 2:54.
35. Sun Y, Selvaraj S, Varma A, Derry S, Sahmoun AE, Singh BB. Increase in serum Ca2+/Mg2+ ratio promotes proliferation of prostate cancer cells by activating TRPM7 channels. J Biol Chem 2013; 288:255-263.
36. Hoyer-Hansen M, Bastholm L, Szyniarowski P, et al. Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-beta, and Bcl-2. Mol Cell 2007; 25:193-205.
37. Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM, Castellon EA. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl 2007; 28:282-293.
38. Bishayee A. Cancer prevention and treatment with resveratrol: From rodent studies to clinical trials. Cancer Prev Res 2009; 2:409-418.
39. Kondratskyi A, Yassine M, Slomianny C, et al. Identification of ML-9 as a lysosomotropic agent targeting autophagy and cell death. Cell Death Dis 2014; 5:e1193.
40. Borowiec AS, Bidaux G, Pigat N, Goffin V, Bernichtein S, Capiod T. Calcium channels, external calcium concentration and cell proliferation. Eur J Pharmacol 2014; 739:19-25.
41. Chen J, Luan Y, Yu R, Zhang Z, Zhang J, Wang W. Transient receptor potential (TRP) channels, promising potential diagnostic and therapeutic tools for cancer. Biosci Trends 2014; 8:1-10.
42. Roberts-Thomson SJ, Peters AA, Grice DM, Monteith GR. ORAI-mediated calcium entry: Mechanism and roles, diseases and pharmacology. Pharmacol Ther 2010; 127:121-130.
43. Gu P, Zhou YB, Yang DR, Shan YX, Xue BX. Inhibition of stromal interaction molecule 1 and the expression of apoptosis-related proteins in prostate cancer PC-3 cells. Zhonghua Nan Ke Xue 2014; 20:225-228.
44. Wang FM, Galson DL, Roodman GD, Ouyang H. Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses pro-survival XBP1 signaling in human multiple myeloma cells. Exp Hematol 2011; 39:999-1006.
45. Huang TT, Lin HC, Chen CC, et al. Resveratrol induces apoptosis of human nasopharyngeal carcinoma cells via activation of multiple apoptotic pathways. J Cell Physiol 2011; 226:720-728.
46. Ma Y, Hendershot LM. The unfolding tale of the unfolded protein response. Cell 2001; 107:827-830.
47. Li J, Lee AS. Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 2006; 6:45-54.
48. Schonthal AH. Pharmacological targeting of endoplasmic reticulum stress signaling in cancer. Biochem Pharmacol 2013; 85:653-666.
49. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: Therapeutic implications. Mol Cancer Ther 2011; 10:1533-1541.
50. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 2012; 12:401-410.
51. Guo XL, Li D, Hu F, et al. Targeting autophagy potentiates chemotherapy-induced apoptosis and proliferation inhibition in hepatocarcinoma cells. Cancer Lett 2012; 320:171-179.
52. Mukhtar E, Adhami VM, Khan N, Mukhtar H. Apoptosis and autophagy induction as mechanism of cancer prevention by naturally occurring dietary agents. Curr Drug Targets 2012; 13:1831-1841.
53. Zhang X, Chen LX, Ouyang L, Cheng Y, Liu B. Plant natural compounds: Targeting pathways of autophagy as anti-cancer therapeutic agents. Cell Prolif 2012; 45:466-476.
54. Scarlatti F, Maffei R, Beau I, Codogno P, Ghidoni R. Role of non-canonical Beclin 1-independent autophagy in cell death induced by resveratrol in human breast cancer cells. Cell Death Differ 2008; 15:1318-1329.
55. Kartal M, Saydam G, Sahin F, Baran Y. Resveratrol triggers apoptosis through regulating ceramide metabolizing genes in human K562 chronic myeloid leukemia cells. Nutr Cancer 2011; 63:637-644.
56. Puissant A, Robert G, Fenouille N, et al. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res 2010; 70:1042-1052.
57. Opipari AW, Jr., Tan L, Boitano AE, Sorenson DR, Aurora A, Liu JR. Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res 2004; 64:696-703.
58. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007; 3:542-545.
59. Kabeya Y, Mizushima N, Yamamoto A, Oshitani-Okamoto S, Ohsumi Y, Yoshimori T. LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. J Cell Sci 2004; 117:2805-2812.
60. Sun H, Wang Z, Yakisich JS. Natural products targeting autophagy via the PI3K/Akt/mTOR pathway as anticancer agents. Anticancer Agents Med Chem 2013; 13:1048-1056.
61. Beauchamp EM, Platanias LC. The evolution of the TOR pathway and its role in cancer. Oncogene 2013; 32:3923-3932.
62. Persad S, Attwell S, Gray V, et al. Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 2000; 97:3207-3212.
63. Bitting RL, Armstrong AJ. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer 2013; 20:R83-R99.
64. Majumder PK, Sellers WR. Akt-regulated pathways in prostate cancer. Oncogene 2005; 24:7465-7474.
65. Peng H, Liu J, Sun Q, et al. MTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development. Oncogene 2013; 32:4702-4711.